Apollon Wealth Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Apollon Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265K	Sell	7,834 -392	-5%	-$13.1K	﹤0.01%	1348
2026 Q1	$248K	Buy	+8,226	New	+$265K	﹤0.01%	1211
2024 Q1	–	Sell	-26,439	Closed	-$276K	–	1161
2023 Q4	$276K	Buy	26,439 +60	+0.2%	+$560	0.01%	871
2023 Q3	$269K	Sell	26,379 -3,649	-12%	-$34K	0.01%	737
2023 Q2	$226K	Sell	30,028 -285	-0.9%	-$2.31K	0.01%	823
2023 Q1	$268K	Buy	30,313 +6,685	+28%	+$66.1K	0.02%	712
2022 Q4	$215K	Sell	23,628 -235	-1%	-$2.05K	0.02%	763
2022 Q3	$193K	Sell	23,863 -200	-0.8%	-$1.77K	0.02%	726
2022 Q2	$181K	Buy	24,063 +4,125	+21%	+$35.9K	0.02%	690
2022 Q1	$187K	Sell	19,938 -1,600	-7%	-$13.4K	0.01%	701
2021 Q4	$173K	Buy	+21,538	New	+$194K	0.01%	722

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Apollon Wealth Management's TEVA Position: Q2 2026 in Review

Apollon Wealth Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 4.8% in Q2 2026, selling an estimated $13.1K and leaving 7,834 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1348.

Apollon Wealth Management first reported a position in TEVA in Q4 2021 and has held it in 11 quarters since. The position peaked at $276K in Q4 2023. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Apollon Wealth Management held 7,834 shares of Teva Pharmaceutical Industries Limited worth $265K as of Q2 2026.
Apollon Wealth Management sold 392 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $13.1K.
Teva Pharmaceutical Industries Limited made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1348 holding.
Apollon Wealth Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2021 and has held it in 11 quarters since.
Apollon Wealth Management's Teva Pharmaceutical Industries Limited position peaked at $276K in Q4 2023.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.